Presumed tuberculosis-related scleritis.


Journal

The British journal of ophthalmology
ISSN: 1468-2079
Titre abrégé: Br J Ophthalmol
Pays: England
ID NLM: 0421041

Informations de publication

Date de publication:
04 2023
Historique:
received: 07 06 2021
accepted: 25 10 2021
pubmed: 21 11 2021
medline: 25 3 2023
entrez: 20 11 2021
Statut: ppublish

Résumé

To evaluate the clinical characteristics and therapeutic outcome of patients with recurrent scleritis of unknown demonstrable aetiology and positive QuantiFERON-TB Gold In-Tube test (QFT). Retrospective chart review of the demographic, clinical, laboratory and therapeutic outcome data of 15 patients. Clinical characteristics as well as remission rate after standard antituberculous therapy (ATT) were assessed. There were 9 men and 6 women with a mean age of 48.9 years (range, 32-73). Scleritis was diffuse in 10 patients (66.6%) and nodular in 5 patients (33.3%), 1 of them with concomitant posterior scleritis. It was bilateral in 7 patients (46.6%) and recurrent in all of them. Scleritis appeared after prior uveitis (10 patients, 66.6%) and/or with concomitant uveitis (5 patients, 33.3%) or peripheral keratitis (5 patients, 33.3%). Previous ocular surgery was found in 7 patients (46.6%). Previous extraocular tuberculosis (TB) infection or previous TB contact was detected in 11 patients (73.3%). No radiologic findings of active extraocular TB were detected. ATT was used in 15 patients, sometimes with the addition of systemic corticosteroids (5 patients) and methotrexate (1 patient); 14 patients achieved complete remission (93.3%). Presumed TB-related scleritis may appear in recurrent scleritis of unknown origin and positive QFT. It may occur after prior uveitis and/or concomitantly with uveitis or peripheral keratitis, and it may be triggered by previous ocular surgery. No patients had evidence of concurrent active extraocular infection, although many had previous TB infection or TB contact. ATT was effective, sometimes with the addition of systemic corticosteroids and methotrexate.

Identifiants

pubmed: 34799367
pii: bjophthalmol-2021-319799
doi: 10.1136/bjophthalmol-2021-319799
doi:

Substances chimiques

Antitubercular Agents 0
Methotrexate YL5FZ2Y5U1
Adrenal Cortex Hormones 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

495-499

Informations de copyright

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Maite Sainz de La Maza (M)

Ophthalmology, Hospital Clinic de Barcelona, Barcelona, Spain sainzdelamazamaite@gmail.com.

Ines Hernanz (I)

Ophthalmology, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain.

Aina Moll-Udina (A)

Ophthalmology, Hospital Clinic de Barcelona, Barcelona, Spain.

Marina Mesquida (M)

Ophthalmology, Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain.

Alfredo Adan (A)

Ophthalmology, Hospital Clinic de Barcelona, Barcelona, Spain.

Jose Antonio Martinez (JA)

Department of Infectious Diseases, Hospital Clinic de Barcelona, Barcelona, Spain.

Gerard Espinosa (G)

Autoimmune Diseases, Hospital Clínic de Barcelona, Barcelona, Spain.

Víctor Llorenç (V)

Ophthalmology, Hospital Clinic de Barcelona, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH